Company Analysis
Sign in

Century Therapeutics, Inc. (IPSC)

Nasdaq: IPSC · Biological Products, (No Diagnostic Substances) · Philadelphia, PA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.7
◀ Past 4.6● Present 6.2▶ Future 6.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 12, 2026Mar 19, 2025Mar 14, 2024Mar 16, 2023Mar 17, 2022·
Revenue109,1646,5892,2355,199··
Research and development95,667107,24492,71097,17375,64839,681
General and administrative24,00333,15534,70631,85719,2359,495
Total operating expenses126,433144,726148,781139,03094,88353,898
Operating income-17,269-138,137-146,546-133,831-94,883-53,898
Interest expense··5401,017r1,275381
Interest and investment income7,34613,00712,677···
Other income (expense), net275354-3832,990-898323
Total non-operating income (expense)7,62113,36111,7542,990··
Income before income taxes-9,648-124,776-134,792-130,841-95,781-53,575
Income tax expense-681,7901,8819143·
Net income including non-controlling interests-9,580-126,566-136,673-130,932-95,824-53,575
Net income-9,580-126,566-136,673-130,932-95,824-53,575
Earnings per share, basic-0.14-1.61-2.30-2.27-2.96-7.16
Earnings per share, diluted-0.14-1.61-2.30r-2.96r-2.96-7.16
Weighted average shares, basic86,556,51578,648,95859,314,38957,755,84232,392,5547,481,861
Weighted average shares, diluted86,556,51578,648,95859,314,389r32,392,554r32,392,5547,481,861
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InterestIncomeOther
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton IPSC · research, not advice